TargetMol

Aprocitentan

Product Code:
 
TAR-T7817
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7817-1mg1mg£163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7817-5mg5mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7817-1mL1 mL * 10 mM (in DMSO)£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7817-10mg10mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7817-25mg25mg£576.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7817-50mg50mg£790.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7817-100mg100mg£1,050.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7817-500mg500mg£2,038.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Aprocitentan is ETA and ETB antagonist .
CAS:
1103522-45-7
Formula:
C16H14Br2N6O4S
Molecular Weight:
546.19
Pathway:
GPCR/G Protein
Purity:
0.9917
SMILES:
NS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1
Target:
Endothelin Receptor

References

Trensz F , Bortolamiol C , Kramberg M , et al. PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION[J]. Journal of Pharmacology & Experimental Therapeutics, 2019.